Aborted melanoma trial ends pharma alliance

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 7
Volume 18
Issue 7

Synta and GlaxoSmithKline will end their agreement to develop and market elesclomol for the treatment of metastatic melanoma after lackluster results from the SYMMETRY trial.

Synta and GlaxoSmithKline will end their agreement to develop and market elesclomol for the treatment of metastatic melanoma after lackluster results from the SYMMETRY trial.

The late-stage trial evaluated elesclomol plus paclitaxel vs paclitaxel alone in patients with metastatic melanoma. The study was suspended because of a higher mortality rate among patients in the elesclomol treatment arm along with other safety concerns.

The deal between the two companies is expected to be terminated no later than September 10, 2009, after which worldwide rights to elesclomol will revert to Synta.

Articles in this issue
Letrozole appears less detrimental than tamoxifen to cognitive function in breast ca
Accelerated whole-breast irradiation does more with less after lumpectomy
RIBBON-1 results bolster bevacizumab as add-on to standard Rx for metastatic breast cancer
PET/CT Indicates if Early Neoadjuvant Rx is Making the Grade in Sarcoma Patients
Less is more when it comes to serial CA125 testing in ovarian cancer
Treatment varies widely in chronic myeloid leukemia
Should expectant management serve as the primary treatment option in prostate cancer?
Oncology takes blame for rising healthcare cost
Healthcare advocates call for universal coverage, acknowledge challenges
NSABP chair admits ‘failure’ in C-08 trial, denies defeat
Gemcitabine, capecitabine regimens equal in breast ca mets
Study ties survival to inflammatory markers in breast cancer
Canadians rally for national standards for breast ca testing
Trio of genes plays role in breast ca mets to brain
Micromet BiTE antibody eliminates leukemia cells
Related Videos
Experts on myeloma
Related Content
Jonathan Zager, MD, spoke about the use of observation vs systemic immunotherapy to treat patients with stage IIIA and IIIB melanoma.

Selecting Observation Vs Immunotherapy in Advanced Melanoma

April 2nd 2024
Article

Jonathan Zager, MD, spoke about the use of observation vs systemic immunotherapy to treat patients with stage IIIA and IIIB melanoma.

OncView™ Podcast: Immunotherapy Response Monitoring in Melanoma

OncView™ Podcast: Immunotherapy Response Monitoring in Melanoma

April 8th 2022
Podcast

John Kirkwood, MD, PhD, discussed considerations for treating patients with melanoma using immunotherapy and how to properly monitor responses.

The DermaSensor device demonstrates a high rate of sensitivity in the detection of more than 200 types of skin cancers in a clinical study.

FDA Clears Non-Invasive AI Device for Skin Cancer Detection

January 18th 2024
Article

The DermaSensor device demonstrates a high rate of sensitivity in the detection of more than 200 types of skin cancers in a clinical study.

On this episode of CancerNetwork’s podcast, Emily Smith, MD, discussed a patient case of basal cell carcinoma she and colleagues published in the journal ONCOLOGY.

Oncology Peer Review On-The-Go: Patient Case of Metastatic Basal Cell Carcinoma Arising From a Carcinosarcoma

February 14th 2022
Podcast

On this episode of the Oncology® Peer Review On-The-Go, Emily Smith, MD, discussed a patient case of basal cell carcinoma she and colleagues published in the journal ONCOLOGY®.

Individualized Neoantigen Therapy/Pembrolizumab Improves RFS in Melanoma

Individualized Neoantigen Therapy/Pembrolizumab Improves RFS in Melanoma

December 18th 2023
Article

mRNA-4157 is being evaluated in combination with pembrolizumab as part of the phase 2b KEYNOTE-942/mRNA-4157-P201 trial in patients with completely resected, high-risk, stage III to IV melanoma.

Treatment with mRNA-4157 plus pembrolizumab yields benefits in resected melanoma subgroups in the phase 2 KEYNOTE-942 trial, including those with BRAF-mutated tumors.

mRNA Vaccine/Pembrolizumab Significantly Improves RFS in Resected Melanoma

October 23rd 2023
Article

Treatment with mRNA-4157 plus pembrolizumab yields benefits in resected melanoma subgroups in the phase 2 KEYNOTE-942 trial, including those with BRAF-mutated tumors.